Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-09-18
2007-09-18
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S139100, C530S387100, C530S387300, C530S387900, C530S388220
Reexamination Certificate
active
10774192
ABSTRACT:
The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
REFERENCES:
patent: 6326472 (2001-12-01), Timans et al.
patent: 0 464 533 (1991-06-01), None
patent: WO99/19480 (1998-10-01), None
Bacher et al. (2004). The NF-KB pathway as a potential target for autoimmune disease therapy. Current Pharmaceutical Design. 10:2827-2837.
Lejeune et al. (2002). The interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. The Journal of Biological Chemistry. 37:33676-33682.
Wullaert et al. (2006). Mechanisms of crosstalk between TNF-induced NF-KB and JNK activation in hepatocytes. Biochemical Pharmacology. 72:1090-1101.
Li et al. (2001). IL-1-induced NFKB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK). Proc. Natl. Acad. Sci. USA 98(8):4461-4465.
Debets et al. (2000). IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. The Journal of Immunology. 165:4950-4956.
Gillespie et al. (1998). Interleukin-18: perspectives on the newest interleukin. Cytokine and Growth Factor Reviews. 9(2):109-116.
Adachi et al. (1998). Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9:143-150.
Bonnert, T. P. et al., “The cloning and characterization of human MyD88: a member of an IL-1 receptor related family,”FEBS Letters, 402:81-84, 1997.
Born T. L. et al., “Cloning of a novel receptor subunit, AcPL, required for Interleukin-18 signaling,”J. Biol. Chem., 273(45) 29445-29450, 1998.
Greenfeder S. A. et al., “Molecular cloning and characterization of a second subunit of the Interleukin 1 receptor complex,”J. Biol. Chem., 270(23):13757-13765, 1995.
Lovenberg, T. W. et al., “Cloning of a cDNA encdoding a novel interleukin-1 receptor related protein (IL1R-rp2),”J. Neuroimmunol., 70:113-122, 1996.
Parnet P. et al., “IL-1Rrp is a novel receptor-like molecule similar to the type I Interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP,”J. Biol. Chem., 271(8):3967-3970, 1996.
Rock, F. L. et al., “A family of human receptors structurally related to Drosophila Toll,”Proc. Natl. Acad. Sci. USA, 95:588-593, 1998.
Thomassen, E. et al., “Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1,”J. Interferon Cytokine Res., 18:1077-1088, 1998.
Torigoe K. et al., “Purification and characterization of the human Interleukin-18 receptor,”J. Biol. Chem., 272(41):25737-25742, 1997.
Born Teresa L.
Sims John E.
Henry Janis C.
Immunex Corporation
Lockard Jon M
Saoud Christine J.
Wrona Thomas J.
LandOfFree
ACPL antibodies and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ACPL antibodies and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ACPL antibodies and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774710